Amarin Reports First Quarter 2020 Financial Results and Provides Update on Operations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amarin Corporation (AMRN) PT Raised to $8 at Jefferies
April 30, 2020 12:26 PM EDTJefferies analyst Michael Yee raised the price target on Amarin Corporation (NASDAQ: AMRN) to $8.00 (from $7.00) while maintaining a Hold rating.
... MoreAmarin Corp. (AMRN) Tops Q1 EPS by 1c, Revenues Beat
April 30, 2020 5:41 AM EDTAmarin Corp. (NASDAQ: AMRN) reported Q1 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $155 million versus the consensus estimate of $137.43 million.
Key recent Amarin achievements include:
Record revenue: Net total revenue reached a record high of $155.0 million in Q1 2020 as compared to $73.3 in Q1 2019, an increase of approximately 112% primarily reflecting increased VASCEPA® (icosapent ethyl) prescription growth in the United States augmented by $6.7 million net product revenue from VASCEPA sales outside of the United States.Commercial expansion: Increased size of U.S. sales force for... More